Research programme: liver X receptor agonists - Alexar TherapeuticsAlternative Names: A 110
Latest Information Update: 15 Dec 2015
At a glance
- Originator Alexar Therapeutics
- Mechanism of Action Liver X receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Dermatitis
Most Recent Events
- 02 Jan 2014 Early research in Dermatitis in USA (Parenteral)
- 02 Jan 2014 Investigation in Dermatitis in USA (Topical, Parenteral)